Li Naikun, Wang Xiaohui, Zhang Hongju, Wang Haiyong
Department of Oncology, Central Hospital of Yidu affiliated to Weifang Medical College, Weifang.
Research Service Office, Shandong Liaocheng People's Hospital.
Medicine (Baltimore). 2018 Oct;97(40):e12686. doi: 10.1097/MD.0000000000012686.
Women diagnosed with breast cancer at young age often have poorprognoses. Yet, few studies have focused on the prognoses of young men with breast cancer. We therefore used Surveillance, Epidemiology, and End Results (SEER) population-based data and identified 151 male patients with breast cancer aged <40 years between 1988 and 2012. Propensity score matching analysis was used to balance the clinical variables among different groups. Kaplan-Meier curves were applied to compare the survival differences. The subgroup variables on cancer-specific survival (CSS) and overall survival (OS) were analyzed by the Cox proportional hazard model. Results showed that male patients with breast cancer aged <40 had a significant OS benefit compared with those aged ≥40 years (P < .001). The significant difference of the CSS was not found (P > .05). Compared with the male patients with breast cancer aged ≥40, those aged <40 had significant OS benefit in most subgroups (P < .05). Compared with the female patients with breast cancer aged <40, the male patients with breast cancer aged <40 had worse OS and CSS benefit only in the subgroup with progesterone receptor and estrogen receptor positive (P < .05). In conclusion, we demonstrated that young male patients with breast cancer had better OS compared with elder male patients with breast cancer. However, the survival benefit was not found compared with young female patients with breast cancer.
年轻时被诊断出患有乳腺癌的女性通常预后较差。然而,很少有研究关注年轻男性乳腺癌患者的预后情况。因此,我们使用基于监测、流行病学和最终结果(SEER)的人群数据,确定了1988年至2012年间151名年龄小于40岁的男性乳腺癌患者。采用倾向得分匹配分析来平衡不同组间的临床变量。应用Kaplan-Meier曲线比较生存差异。通过Cox比例风险模型分析癌症特异性生存(CSS)和总生存(OS)的亚组变量。结果显示,年龄小于40岁的男性乳腺癌患者与年龄≥40岁的患者相比,OS有显著获益(P<0.001)。未发现CSS有显著差异(P>0.05)。与年龄≥40岁的男性乳腺癌患者相比,年龄<40岁的患者在大多数亚组中OS有显著获益(P<0.05)。与年龄<40岁的女性乳腺癌患者相比,年龄<40岁的男性乳腺癌患者仅在孕激素受体和雌激素受体阳性的亚组中OS和CSS获益更差(P<0.05)。总之,我们证明了年轻男性乳腺癌患者与老年男性乳腺癌患者相比OS更好。然而,与年轻女性乳腺癌患者相比未发现生存获益。